Emergent BioSolutions (NYSE: EBS)Â has received a potential two-year, $100 million contract from the Biomedical Advanced Research and Development Authority to
SRI International has received a pair of contracts worth a combined $90 million to help the Biomedical Advanced Research and Development
The Department of Health and Human Services has awarded Emergent BioSolutions a five-year, $198.7 million contract to further mature the
The Department of Health and Human Services has awarded a potential $173.6 million contract to Sanofi Pasteur for work to develop inactivated vaccine
Altimmune has received a potential five-year, $120.2 million contract from the Biomedical Advanced Research and Development Authority to conduct clinical
The Biomedical Advanced Research and Development Authority has awarded Emergent BioSolutions (NYSE: EBS)Â a potential $21.9 million task order to develop
The Department of Health and Human Services has tapped Emergent BioSolutions to further develop a new anthrax vaccine under a 30-month, $31